Flerie Skips Dividends to Fund Breakthrough Myasthenia Gravis Drug TOL2

Flerie has taken a major step in its growth strategy by approving a bonus share issue for its shareholders. The move comes as the company reinforces its focus on developing TOL2, a drug candidate aimed at treating the autoimmune disease myasthenia gravis. Instead of receiving dividends, investors will see their funds redirected into advancing this key project.

The decision was finalised at the annual general meeting in March 2026, with May 18, 2026, marked as the record date for processing the bonus share allocations. The bonus share issue was greenlit by shareholders during the March 2026 annual general meeting. Under the plan, no dividends will be paid out for the previous fiscal year. Instead, the funds will be reinvested into product development, particularly for TOL2.

Flerie has also completed the integration of Toleranzia AB, a company previously focused on autoimmune treatments. While Toleranzia's operational business has since been transferred to Bonsai Biotherapeutics AB, its legacy project—TOL2—remains central to Flerie's pipeline. The drug is now in a critical phase, with clinical trials progressing in several European markets.

The record date for shareholders to receive bonus shares has been set for May 18, 2026. This date will determine eligibility for the allocation, ensuring the process is handled efficiently in shareholders' accounts. Analysts have highlighted TOL2 as a potential game-changer in treating myasthenia gravis, though its development remains closely watched in the coming months. The bonus share issue reflects Flerie's commitment to accelerating TOL2's development without distributing dividends. Shareholders will see their investment redirected into the company's flagship project, with May 18, 2026, as the key date for processing allocations. The outcome of ongoing trials will determine the drug's future impact on autoimmune treatment options.